Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sar-407899 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 known ✓ | Q13464 | 15/20 | 0.97 |
| ▸ | ROCK2 known ✓ | O75116 | 3/20 | 0.97 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.97 |
| ▸ | PRKACA | P17612 | 1/20 | 0.97 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.97 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.97 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.97 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.97 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.97 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.97 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.97 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.97 |
| ▸ | PRKX | P51817 | 1/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.71 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sar-407899 Free Base SCHEMBL15765982 | 0.99 | ROCK1 (0.95) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| Sar-407899 Free Base SCHEMBL14480269 | 0.99 | ROCK1 (0.95) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| Sar-407899 Free Base SCHEMBL29375847 | 0.99 | ROCK1 (1.00) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| Sar-407899 Free Base SCHEMBL952213 | 0.99 | ROCK1 (1.00) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| Sar-407899 Free Base SCHEMBL18600639 | 0.94 | ROCK1 (0.86) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| Sar-407899 Free Base SCHEMBL15765980 | 0.94 | ROCK1 (0.86) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL3219972 | 0.94 | ROCK1 (1.00) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| Sar-407899 Free Base SCHEMBL15765996 | 0.91 | ROCK1 (0.80) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL4007481 | 0.91 | ROCK1 (1.00) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL953733 | 0.91 | ROCK1 (1.00) | ROCK1ROCK2PRKCDPRKACAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | claimed |
| US-20240299409-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2024-09-12 | — | — | US | claimed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | claimed |
| EP-2729461-B1 | POLYMORPHS OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI SA (FR) | 2016-01-20 | — | — | EP | claimed |
| EP-2729460-B1 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI SA (FR) | 2016-01-13 | — | — | EP | claimed |
| US-20140221656-A1 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI (FR) | 2014-08-07 | — | — | US | claimed |
| EP-2729461-A1 | POLYMORPHS OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI (FR) | 2014-05-14 | — | — | EP | claimed |
| EP-2729460-A1 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI (FR) | 2014-05-14 | — | — | EP | claimed |
| US-8710078-B2 | Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride | SANOFI (FR) | 2014-04-29 | — | — | US | claimed |
| US-8598201-B2 | Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride | SANOFI (FR) | 2013-12-03 | — | — | US | claimed |
| WO-2013007519-A1 | POLYMORPHS OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI (FR) | 2013-01-17 | — | — | WO | claimed |
| WO-2013007518-A1 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI (FR) | 2013-01-17 | — | — | WO | claimed |
| US-20130012444-A1 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI (FR) | 2013-01-10 | — | — | US | claimed |
| US-20130012479-A1 | POLYMORPHS OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SANOFI (FR) | 2013-01-10 | — | — | US | claimed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| WO-2025094914-A1 | TRANSPLANTATION DEVICE CAPABLE OF ENCAPSULATING CELLS THEREIN AND USE THEREOF | 株式会社VC Cell Therapy | 2025-05-08 | — | — | WO | disclosed |
| CN-119630643-A | Process and intermediate compounds for the preparation of 6-substituted-1- (2H) -isoquinolinones | 瓦洛健康公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2008077550-A1 | SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1910333-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012421-A1 | PIPERIDINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | ROCK1 4/4885ROCK2 5/4885PRKCD 553/4885 |
| US-20240299409-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | ROCK1 2/4885ROCK2 1/4885PRKCD 320/4885 |
| US-20130012479-A1 | POLYMORPHS OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | SFPQ, POLQ, SYNCRIP | ROCK1 1633/4885ROCK2 2018/4885PRKCD 431/4885 |
| US-20140221656-A1 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | AQP1, AQP3, AQP4 | ROCK1 1082/4885ROCK2 1684/4885PRKCD 2210/4885 |
| US-20130012444-A1 | CRYSTALLINE SOLVATES OF 6-(PIPERIDIN-4-YLOXY)-2H-ISOQUINOLIN-1-ONE HYDROCHLORIDE | AQP1, AQP3, AQP4 | ROCK1 1082/4885ROCK2 1684/4885PRKCD 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.